Global pandemic numbers rose by 3 million last week, bringing the grand total to over 67 million cases as governments and suppliers scramble to prepare for the distribution of vaccines. Hopes of a refreshed stimulus package in the US were reignited as senators proposed a bipartisan package worth USD0.9 trillion. US-China tensions continue, as the US announced more restrictions against US-listed Chinese equities and military linked-companies. Gold price rebounded throughout the week with hopes of new stimulus aid, rising infection in the US and the weakening dollar.
In the News
- The world added over 3 million new coronavirus infections last week, bringing the total to over 67 million cases, with 1.5 million deaths recorded. The US saw record high daily infections for 3 days in a row, and reported over 2,000 deaths daily for two weeks.
- Vaccine wise, Pfizer obtained approval from the UK for emergency use for its vaccine in the country, but was hampered by news of a supply chain disruption for the vaccine. However, it was later affirmed that the delivery for 50 million doses promised for this year continues to be on track.
- Hopes for an added stimulus in the US was reignited last week after news that a bipartisan group of senate members proposed a USD908 billion package. The US Treasury, which previously requested the return of emergency lending funds from the Federal Reserve, urged legislators to tap into CARES Act funds to provide targeted relief.
- Positive momentum persevered in US markets last week, with all major indices ending the week at record highs. The best performing index last week was the tech-focused Nasdaq, recording 1.93% of gains throughout the week, while the S&P500 index gained 1.48% last week.
- However, the performance of the NYSE FANG+ Index was lacklustre as compared to its peers, gaining 1.48% in MYR terms last week as the prospects of a reopening led to a correction in bigger tech names. The 2x Leveraged 0830EA saw 3.01% return throughout the week. The ETF has generated a handsome YTD return of 134.55%.
- Chinese markets continued to see gains after PMI readings hit record highs, solidifying its recovery from the pandemic despite news that the US Defense Department added 4 more Chinese companies into its banned list of Chinese companies related to the military. Over the week, CSI 300 Index gained 2.24% while the Shanghai Composite Index were up 1.60% in MYR terms.
- However, there was a divide in performance of A-shares versus offshore Chinese equities, as the House of Representatives in the US accelerates its vote on a bill that would threaten Chinese equities listed in the US, potentially affecting companies like Pinduoduo and Baidu, which do not have a second listing outside of the US.
- As a result, the S&P New China Sectors Ex A Share Index, which invests into ex-A shares recorded a dip of 1.80% throughout the week, reacting to the negative news. While the 0829EA also dipped by 1.73% last week, the ETF is still recording YTD returns of 31.88% in MYR terms.
- Locally, the broader market ended the week with 0.89% gains as market rotation activity continued, buying into stocks that would benefit from economic recovery and selling down healthcare names following more positive vaccine news. Throughout the week, the Dorsey Wright Technical Leaders Malaysia MYR Index managed to outperform the broader index, recording 3.94% of gains while the 0836EA followed suit, ending the week 3.46% in the green.
- Gold prices reversed its negative momentum last week, rebounding 1.54% throughout the week. The rebound could be attributed to the weakened dollar movement throughout the week, coupled with regained hopes of a stimulus package in the US and record high pandemic infection numbers. During the week, the 0828EA upped 1.51%, with a YTD return of 18.53% in MYR terms.
On the Economic Data Front
- US economy slowing down, data shows:
- Non-farm payrolls growth recorded at 245,000, missing expectations by almost half.
- Unemployment rate fell to a pandemic low of 6.7%, but could be partly attributed to a decline in labour force participation rate.
- Pending home sales data shows drop for the second consecutive month in October.
- China PMI readings shows extended recovery:
- Official manufacturing PMI numbers recorded at 52.1 in November, its 9th consecutive monthly growth.
- Private manufacturing PMI recorded at 54.9, beating expectations to its highest gauge since 2010 as it records its 7th monthly consecutive expansion.
Brexit negotiations drag on, EU to push through recovery fund:
- Post-Brexit negotiations between the EU and UK continues as disagreements persists, while France threatens to veto if the deal does not align with its interests.
- The European Commission plans to exclude Poland and Hungary from its pandemic recovery fund which is part of its proposed 7-year budget should objections persist.
ETF strategies at TradePlus
A look at the performance of the TradePlus ETFs, and major global indices
Learn more about TradePlus ETFs
Disclaimer: This article has been prepared by Affin Hwang Asset Management Berhad (hereinafter referred to as “Affin Hwang AM”) specific for its use, a specific target audience, and for discussion purposes only. All information contained within this presentation belongs to Affin Hwang AM and may not be copied, distributed or otherwise disseminated in whole or in part without written consent of Affin Hwang AM. The information contained in this presentation may include, but is not limited to opinions, analysis, forecasts, projections and expectations (collectively referred to as “Opinions”). Such information has been obtained from various sources including those in the public domain, are merely expressions of belief. Although this presentation has been prepared on the basis of information and/or Opinions that are believed to be correct at the time the presentation was prepared, Affin Hwang AM makes no expressed or implied warranty as to the accuracy and completeness of any such information and/or Opinions. As with any forms of financial products, the financial product mentioned herein (if any) carries with it various risks. Although attempts have been made to disclose all possible risks involved, the financial product may still be subject to inherent risk that may arise beyond our reasonable contemplation. The financial product may be wholly unsuited for you, if you are adverse to the risk arising out of and/or in connection with the financial product. Affin Hwang AM is not acting as an advisor or agent to any person to whom this presentation is directed. Such persons must make their own independent assessments of the contents of this presentation, should not treat such content as advice relating to legal, accounting, taxation or investment matters and should consult their own advisers. Affin Hwang AM and its affiliates may act as a principal and agent in any transaction contemplated by this presentation, or any other transaction connected with any such transaction, and may as a result earn brokerage, commission or other income. Nothing in this presentation is intended to be, or should be construed as an offer to buy or sell, or invitation to subscribe for, any securities. Neither Affin Hwang AM nor any of its directors, employees or representatives are to have any liability (including liability to any person by reason of negligence or negligent misstatement) from any statement, opinion, information or matter (expressed or implied) arising out of, contained in or derived from or any omission from this presentation, except liability under statute that cannot be excluded.
Warning Statement: A copy of the Prospectus / Supplemental Prospectus for the TradePlus Shariah Gold Tracker and TradePlus S&P New China Tracker, the Prospectus for the TradePlus DWA Malaysia Momentum Tracker and TradePlus MSCI Asia Ex Japan REITs Tracker, as well as the Master Prospectus for the TradePlus NYSE® FANG+™ Daily (2x) Leveraged Tracker, TradePlus NYSE® FANG+™ Daily (-1x) Inverse Tracker, TradePlus HSCEI Daily (2x) Leveraged Tracker and TradePlus HSCEI Daily (-1x) Inverse Tracker (collectively known as the “TradePlus L&I ETFs”) can be obtained at Affin Hwang Asset Management's (“Affin Hwang AM”) website at www.tradeplus.com.my. Investors are advised to read and understand the contents of the Prospectus dated 28 November 2017 and Supplemental Prospectus dated 2 July 2019 (for TradePlus Shariah Gold Tracker), Prospectus dated 15 January 2019 and Supplemental Prospectus dated 2 July 2019 (for TradePlus S&P New China Tracker), Prospectus dated 9 July 2020 (for TradePlus DWA Malaysia Momentum Tracker), Prospectus dated 9 July 2020 (for TradePlus MSCI Asia Ex Japan REITs Tracker), as well as the Master Prospectus dated 26 November 2019 (for the TradePlus L&I ETFs) before investing. There are fees and charges involved when investing in the funds stated herein. Investors are advised to consider and compare the fees and charges as well of the risks carefully before investing. Investors should make their own assessment of the risks involved in investing and should seek professional advice, where necessary. The price of units and distribution payable, if any, may go down as well as up and past performance of the funds should not be taken as indicative of their future performance. The Securities Commission Malaysia has not reviewed this material and takes no responsibility for the contents of this material and expressly disclaims all liability, however arising from this material.
You may refer to the relevant Licensing Disclosure Statement & Conditions at the respective webpages for each fund available on www.tradeplus.com.my.